UBS Group’s Bellevue Life Sciences Acquisition Corp. Unit BLACU Stock Holding History

UBS Group’s Portfolio BLACU Stock Details BLACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500	Closed	-$5.6K	–	10996
2024 Q4	$5.6K	Hold	500	–	–	﹤0.01%	8632
2024 Q3	$4.92K	Buy	+500	New	+$5.5K	﹤0.01%	8109
2023 Q2	–	Sell	-1,316	Closed	-$13.6K	–	9845
2023 Q1	$13.6K	Buy	+1,316	New	+$13.5K	﹤0.01%	7390

UBS Group's BLACU Position: Q1 2025 in Review

UBS Group sold out of Bellevue Life Sciences Acquisition Corp. Unit (BLACU) in Q1 2025, closing a stake of 500 shares — an estimated $5.6K sold.

UBS Group first reported a position in BLACU in Q1 2023 and held it in 3 quarters. The position peaked at $13.6K in Q1 2023. 0 funds tracked by Wall St. Rank hold BLACU as of Q1 2025.

UBS Group reported no remaining Bellevue Life Sciences Acquisition Corp. Unit position as of Q1 2025 after selling out during the quarter.
UBS Group sold 500 Bellevue Life Sciences Acquisition Corp. Unit shares in Q1 2025, an estimated $5.6K.
UBS Group first reported a position in Bellevue Life Sciences Acquisition Corp. Unit in Q1 2023 and held it in 3 quarters.
UBS Group's Bellevue Life Sciences Acquisition Corp. Unit position peaked at $13.6K in Q1 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Unit as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.